Merck Announces FDA Placed Clinical Hold On KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023 Following Review Of Data By Data Monitoring Committee; FDA Has Determined Risk Of KEYTRUDA In Compination With Pomalidomide Of Lenalidomide Outweigh Potential Benefits
Hal Lindon